Medical Cannabis, Inc. Investment Firm AXIM ® Biotechnologies Broadens Research Department and Announces Dr. Sergei Svarovsky as Chief Scientific Officer of Subsidiary Sapphire Biotech
SAN DIEGO, May 28, 2020/ PRNewswire/– Medical Marijuana, Inc.( OTC: MJNA) (the “Company”), the first-ever publicly traded marijuana business in the United States that introduced the world’s first-ever cannabis-derived nutraceutical products, brand names and supply chain, revealed today that its investment company AXIM ® Biotechnologies, Inc.(OTCQB: AXIM) (” AXIM ® Biotech” or “AXIM”) has expanded its research study department through the establishment of a modern lab in the biotechnology market center of San Diego, Calif. Additionally, appreciated scientist Dr. Sergei Svarovsky will lead the oncology-focused research study group as the Chief Scientific Officer and founder of AXIM’s subsidiary, Sapphire Biotech, Inc.(” Sapphire”).
” This brand-new lab is a giant advance for AXIM to bring its research study completely internal and continue its scientific discoveries at a sped up rate,” stated Dr. Stuart Titus, CEO of Medical Marijuana, Inc. “We are excited to see additional innovations from the group to be led by well-recognized researcher, Dr. Svarovsky.”
AXIM’s new research laboratory is fully equipped for all research study to be done by its own research study group and sits adjacent to a lot of the world’s biggest biotechnology business. This location, along with the density of biotechnology companies in the location, grants AXIM the ability to increase the speed and access of its research study due to nearby analytical services and vital chemistry and biology devices.
Dr. Sergei Svarovsky has been selected as Chief Scientific Officer to supervise this new laboratory and lead Sapphire’s research and item advancement efforts. He holds a Master of Science in Physical Chemistry from Novosibirsk State University, a Doctor of Approach in Physical Organic Chemistry and a Master of Organisation Administration from West Virginia University As a Research Fellow at the National Institute of Health’s (NIH) National Cancer Institute, Dr. Svarovsky’s unique developments made him the distinguished NIH Fellow Award for Research Study Quality (FARE).
” AXIM recently rotated into an exciting new oncology-focused company. Through this new laboratory and Dr. Svarovsky’s management, we intend to provide our talented research group with cutting edge research study resources to continue making amazing discoveries,” stated AXIM ® Biotech CEO John W. Huemoeller II.
For more details about AXIM, please see www.aximbiotech.com
About AXIM ® Biotechnologies
Founded in 2014, AXIM ® Biotechnologies, Inc. (AXIM) is a vertically integrated oncology business developing diagnostic tests for the early detection of cancer, proprietary little molecules drugs not just to treat cancer however also to block transition and establishing unique antibodies for therapeutic and diagnostic usages. AXIM is also establishing brand-new cannabinoid molecules for oncological therapies.
Presently, Sapphire Biotech, Inc.’s diagnostic tool is being used to study the business’s enzyme biomarker to discover pancreatic cancer earlier than flowing tumor cells. Learn more here To find out more, please go to www.AXIMBiotech.com
Medical Cannabis, Inc.’s headquarters remains in San Diego, California, and extra details is readily available at OTCMarkets.com or by checking out www.medicalmarijuanainc.com To see Medical Cannabis, Inc.’s corporate video, click on this link
Shareholders and consumers are likewise encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s store.
This press release might include specific positive declarations and information, as defined within the significance of Area 27 A of the Securities Act of 1933 and Area 21 E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor developed by those sections. This material includes statements about expected future events and/or monetary results that are forward-looking in nature and subject to dangers and unpredictabilities. Such forward-looking statements by definition involve risks, unpredictabilities and other factors, which may trigger the real results, efficiency or achievements of Medical Cannabis, Inc. to be materially various from the declarations made herein.
FDA (FDA) DISCLOSURE
These statements have actually not been examined by the Food and Drug Administration. This item is not intended to diagnose, deal with, cure, or prevent any illness.
Medical Marijuana, Inc. does not offer or disperse any items that are in offense of the United States Controlled Substances Act.
Financier Relations Contact:
P. (858) 283-4016
SOURCE Medical Marijuana, Inc.